Last reviewed · How we verify
CCRE
At a glance
| Generic name | CCRE |
|---|---|
| Also known as | endotoxin, lipopolysaccharide (LPS) |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Fever
- Anxiety
- Vasovagal Reaction
- UTI
Key clinical trials
- Lipopolysaccharide (LPS) Challenge in Depression (PHASE1)
- Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART) (PHASE1)
- Systemic Inflammatory Response to CCRE (PHASE1)
- TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC (PHASE3)
- Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans (PHASE1)
- A Study of Inhalation of 20,000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers (PHASE1)
- Role of TLR4 in Environmental Asthma (PHASE1)
- Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Ctr Reference Endotoxin in Normal Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |